Comparatively, the high-risk group demonstrates elevated proportions of CD8+ T cells, activated CD4+ memory T cells, and Tregs, which serve as effector T cells, fostering tumor immune activation and cytotoxicity against tumor cells, thereby favoring positive clinical outcomes for patients (Dunn et al., 2002). The gene discussed is CD8A; the disease is neoplasm.